Global X U.S. Infrastructure Development ETF PAVE 深 沪
已收盘 08-29 16:00:00 美东时间
46.51
-0.420
-0.89%
华盛通- 最 高46.913
- 今 开46.91
- 成交量 61.74万股
- 最 低 46.315
- 昨 收 46.93
- 总市值 92.09亿
- 52周最高 47.24
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 32.5397
- 委 比 -80.00%
- 总股本 1.98亿
- 历史最高 47.24
- 量 比 0.77
- 振 幅 1.27%
- 历史最低 8.7502
- 每 手 1
- 风险率 3.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reported Earlier, Apellis Wins FDA Approval For EMPAVELI To Treat Rare Kidney Diseases C3G And IC-MPGN With 68% Proteinuria Reduction
Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsBroad label includes adults and adolescents with C3G or
07-29 15:32
大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级
摩根士丹利分析师Judah Frommer表示，这一评级是基于该公司市场地位及近期财务战略所作出的判断。
07-07 11:58
Bowman Consulting Expands Into AI-Driven Data Center Engineering
Bowman Consulting Group Ltd. (NASDAQ: BWMN) acquires e3i Engineers for $2 million, expanding its expertise in data center and energy system design.
07-02 21:00
Apellis Pharmaceuticals Announced A Capped Royalty Purchase Agreement With Sobi Under Which Apellis Will Receive Up To $300M In Exchange For 90% Of Apellis' Future Ex-U.S. Royalties For Aspaveli (Systemic Pegcetacoplan)
Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for
07-01 19:09
EXCLUSIVE: Ford, GM Just Hit A Tariff Wall - Will Margins Crumple On Cost Pressures?
Detroit automakers' stocks tumbled after 50% tariffs were announced on imported steel and aluminum, adding up to $400 to vehicle production costs.
06-05 22:19
Centuri Lands $350 Million In New Contracts, CEO Notes Demand Surge
Centuri Holdings (NYSE: CTRI) secures $350M in new contracts for utility infrastructure upgrades across North America, highlighting strong demand for its services in electric, gas, water, and renewable energy systems.
05-27 22:31
Apellis gets FDA Priority Review for its kidney disease treatment
Apellis Pharmaceuticals (APLS) said on Tuesday that the U.S. FDA has accepted and granted Priority Review designation for EMPAVELI to treat two rare and severe kidney diseases. The FDA has set Prescr...
04-01 21:26
Trump's Metal Tariffs Set Stage For US Steel ETF Gains
Tariffs on metal imports create opportunities in ETFs focused on U.S. steelmakers. Top picks are VanEck Steel, SPDR S&P Metals & Mining, and Global X U.S. Infrastructure Development ETF.
02-12 23:28
Cognizant Reports Fourth Quarter and Full-Year 2024 Results
Fourth quarter revenue of $5.1 billion increased 6.8% year-over-year or 6.7% in constant currency1, at the high end of our guidance range Full-year revenue of $19.7 billion increased 2.0% ye...
02-06 05:01
Top momentum subsectors according to Oppenheimer: capital markets, software, and more
Oppenheimer analysts feel most bullish about industrials (NYSEARCA:XLI), financials (XLF), and technology (XLK) due to the sectors’ relative strength. Ari H. Wald, chief financial analyst at Oppenheim...
01-28 02:00
